Replies to post #369314 on Anavex Life Sciences Corp (AVXL)

[crescentmotor]

However, for what ever reason, they sat on the PDD data for two years.

My investing game plan with AVXL contemplated (1) that a PD Phase 2 would be well underway by now and that (2) AVXL would have filed an NDA for adult Rett's, and that both of those developments would be serving as a backstop for a possible AD appointment. Neither of those things happened and the stock price has languished.
Now I am feeling somewhat exposed with my stock position.

In front of the AD readout, I'm starting to think about the desirability of selling off some of my AVXL stock position (given that the stock price will be extremely exposed) and possibly putting a hedge on the remainder. I still would have enough remaining stock and long-term calls in the event of great AD results.

I'm sure I'm not the only one here contemplating about things.

[Amatuer17]

You say if another P3 is required - I say FDA will ask for another P3 trial and that will be larger to reconfirm the results with larger population.

Your other questions are valid and I do not expect M to give any answers. He clearly has over promise under delivery problem. That is his habit and it will not change. He received big options based on some soft milestones - once the final results come out and if they are not good, he will not get anything further.